Abstract:figure legend This study investigated two rare cystic fibrosis transmembrane conductance regulator (CFTR) variants, S1159F and S1159P, which affect the same amino acid in CFTR by breaking a hydrogen bond (dotted line) with D979, that are associated with different disease phenotypes. S1159P appears to be associated with residual exocrine pancreatic function (pancreatic sufficiency) and S1159F with loss of exocrine pancreatic function (pancreatic insufficiency). Using single‐channel recording in cell‐free membrane patches (the dotted lines indicate where channels are closed and downward deflections correspond to channel openings), both rare variants modestly reduced current flow through CFTR, but markedly inhibited channel gating with S1159F causing the severer impact, which correlates with its disease phenotype. Thus, detailed CFTR investigations explain phenotypic differences, informing treatment with CFTR‐targeted therapies. Some residues in the cystic fibrosis transmembrane conductance regulator (CFTR) channel are the site of more than one CFTR variant that cause cystic fibrosis. Here, we investigated the function of S1159F and S1159P, two variants associated with different clinical phenotypes, which affect the same pore‐lining residue in transmembrane segment 12 that are both strongly potentiated by ivacaftor when expressed in CFBE41o− bronchial epithelial cells. To study the single‐channel behaviour of CFTR, we applied the patch‐clamp technique to Chinese hamster ovary cells heterologously expressing CFTR variants incubated at 27°C to enhance channel residence at the plasma membrane. S1159F‐ and S1159P‐CFTR formed Cl− channels activated by cAMP‐dependent phosphorylation and gated by ATP that exhibited thermostability at 37°C. Both variants modestly reduced the single‐channel conductance of CFTR. By severely attenuating channel gating, S1159F‐ and S1159P‐CFTR reduced the open probability (Po) of wild‐type CFTR by ≥75% at ATP (1 mM); S1159F‐CFTR caused the greater decrease in Po consistent with its more severe clinical phenotype. Ivacaftor (10–100 nM) doubled the Po of both CFTR variants without restoring Po values to wild‐type levels, but concomitantly, ivacaftor decreased current flow through open channels. For S1159F‐CFTR, the reduction of current flow was marked at high (supersaturated) ivacaftor concentrations (0.5–1 μM) and voltage‐independent, identifying an additional detrimental action of elevated ivacaftor concentrations. In conclusion, S1159F and S1159P are gating variants, which also affect CFTR processing and conduction, but not stability, necessitating the use of combinations of CFTR modulators to optimally restore their channel activity. Key points Dysfunction of the ion channel cystic fibrosis transmembrane conductance regulator (CFTR) causes the genetic disease cystic fibrosis (CF). This study investigated two rare pathogenic CFTR variants, S1159F and S1159P, which affect the same amino acid in CFTR, to understand the molecular basis of disease and response to the CFTR‐targeted therapy ivacaftor. Both rare variants diminished CFTR function by modestly reducing current flow through the channel and severely inhibiting ATP‐dependent channel gating with S1159F exerting the stronger adverse effect, which correlates with its association with more severe disease. Ivacaftor potentiated channel gating by both rare variants without restoring their activity to wild‐type levels, but concurrently reduced current flow through open channels, particularly those of S1159F‐CFTR. Our data demonstrate that S1159F and S1159P cause CFTR dysfunction by multiple mechanisms that require combinations of CFTR‐targeted therapies to fully restore channel function.

Characterization of Δ(G970-T1122)-CFTR, the Most Frequent CFTR Mutant Identified in Japanese Cystic Fibrosis Patients

THE STRUCTURAL AND FUNCTIONAL IMPORTANCE OF TYPE II DIVERGENT AMINO ACIDS IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

Three Charged Amino Acids in the Outer Vestibule of CFTR Stabilize the Open Pore Architecture

Structural Mechanisms for Defective CFTR Gating Caused by the Q1412X Mutation, a Severe Class VI Pathogenic Mutation in Cystic Fibrosis.

On the Mechanism of Gating Defects Caused by the R117H Mutation in Cystic Fibrosis Transmembrane Conductance Regulator

Compound heterozygous CFTR variants (Q1352H and 5T; TG13) in a Chinese patient with cystic fibrosis

Genomic Rearrangements in the Cftr Gene: Extensive Allelic Heterogeneity and Diverse Mutational Mechanisms

Two rare variants that affect the same amino acid in CFTR have distinct responses to ivacaftor

A Novel TFG C.793c>g Mutation in a Chinese Pedigree with Charcot‐Marie‐Tooth Disease 2

Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia

CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation

Genetic analysis and functional study of novel CFTR variants in Chinese children with cystic fibrosis

Mutation analysis of the cystic fibrosis transmembrane conductance regulator gene in Chinese congenital absence of vas deferens patients

Whole-Exome Sequencing Identified CFTR Variants in Two Consanguineous Families in China

CFTR function, pathology and pharmacology at single-molecule resolution

Estimation of Chloride Channel Residual Function and Assessment of Targeted Drugs Efficiency in the Presence of a Complex Allele [L467F;F508del] in the CFTR Gene

The Solute Carrier Family 26 Member 9 Is a Modifier of the Rapidly Progressing Cystic Fibrosis Associated with F508del CFTR Mutations

The solute carrier family 26 member 9 modifies rapidly progressing cystic fibrosis associated with homozygous F508del CFTR mutation

Novel gain-of-function mutants identify a critical region within CFTR membrane-spanning domain 2 controlling cAMP-dependent and ATP-independent channel activation

Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222

Curcumin and Genistein Additively Potentiate G551D-CFTR